Revolution Medicines Announces Publication of Scientific Paper Describing Anti-Tumor Immunity Induced by SHP2 Inhibitor in Preclinical Cancer Models
Revolution Medicines, Inc. (RVMD)
Company Research
Source: GlobeNewswire
REDWOOD CITY, Calif., April 29, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced the publication of an original scientific paper in Cancer Research, a journal of the American Association for Cancer Research, describing anti-tumor effects of a SHP2 inhibitor through modulation of key elements of the immune system in preclinical cancer models. These findings demonstrate that inhibition of SHP2, a cellular protein that plays a central role in cell survival and growth, may exert therapeutic anti-tumor effects by modulating multiple arms of the immune response to the tumor in addition to reducing oncogenic signaling within tumor cells themselves. Importantly, these data indicate that these two mechanisms may be additive in their anti-tumor impact. Revolution Medicines is currently evaluating RMC-4630, its potent and orally bioavailable inve
Show less
Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVMD alerts
High impacting Revolution Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
RVMD
News
- Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insight [Yahoo! Finance]Yahoo! Finance
- Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at HC Wainwright from $62.00 to $64.00. They now have a "buy" rating on the stock.MarketBeat
- Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at Needham & Company LLC from $61.00 to $68.00. They now have a "buy" rating on the stock.MarketBeat
- Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at JPMorgan Chase & Co. from $54.00 to $63.00. They now have an "overweight" rating on the stock.MarketBeat
- Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at Piper Sandler from $57.00 to $70.00. They now have an "overweight" rating on the stock.MarketBeat
RVMD
Earnings
- 11/6/24 - Miss
RVMD
Sec Filings
- 11/19/24 - Form 4
- 11/15/24 - Form 144
- 11/15/24 - Form 4
- RVMD's page on the SEC website